Inactive

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Maine Molecular, Inc. for the purchase of Warrior Panel Verification Kits. Warrior Pane... The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Maine Molecular, Inc. for the purchase of Warrior Panel Verification Kits. Warrior Panel is an in vitro diagnostic device for presumptive diagnosis of Ebola, Marburg, QFever, Tularemia, Plague, and Anthrax. The technology to detect these biothreat agents are proprietary to the Department of Defense. In order to for LRN laboratories to comply with Clinical Laboratory Improvement Amendments (CLIA) regulations to test patient specimens, Control and Verification panels to detect each biothreat agent individually are required. Because the panels to be made are proprietary to the Department of Defense, no other manufacturer can produce the Warrior panel control and verification panels. Maine Molecular, Inc is the only company that can provide control and verification panels of this nature to the CDC as they are the only company with whom the Department of Defense works to create these materials. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement. This notice of intent is not a request for competitive quotations; however, all responses received within five (5) days of the issuance of this notice will be reviewed by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Any response should be emailed to contract specialist at ezj7@cdc.gov by COB 29 June 2021.